Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.66 |
| ▸ | MEN1 | O00255 | 10/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.66 |
| ▸ | LMNA | P02545 | 7/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14082583 | 0.89 | MAPT (0.63) | MAPTMEN1KMT2AKDM4ELMNA | |
| SCHEMBL4725265 | 0.87 | NPY5R (0.72) | MAPTMEN1KMT2AKDM4ELMNA | |
| SCHEMBL7722872 | 0.87 | MAPT (0.75) | MAPTMEN1KMT2AKDM4ELMNA | |
| SCHEMBL20945432 | 0.86 | MAPT (0.51) | MAPTMEN1KMT2AKDM4ELMNA | |
| SCHEMBL4728615 | 0.83 | NPY5R (0.78) | MAPTMEN1KMT2AKDM4ELMNA | |
| SCHEMBL6226561 | 0.81 | MAPT (0.74) | MAPTMEN1KMT2AKDM4ELMNA | |
| SCHEMBL14252937 | 0.81 | MAPT (0.64) | MAPTMEN1KMT2AKDM4ELMNA | |
| SCHEMBL4727129 | 0.81 | MAPT (0.73) | MAPTMEN1KMT2AKDM4ELMNA | |
| SCHEMBL4728014 | 0.81 | MAPT (0.72) | MAPTMEN1KMT2AKDM4ELMNA | |
| SCHEMBL4725807 | 0.81 | MAPT (0.72) | MAPTMEN1KMT2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147752-A1 | Carbazole derivatives for the treatment of NPY related diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-07-29 | — | — | US | claimed |
| EP-1395578-A1 | CARBAZOLE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NPY RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 2004-03-10 | — | — | EP | claimed |
| WO-2002096902-A1 | CARBAZOLE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NPY RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2002-12-05 | — | — | WO | claimed |
| WO-2008021745-A2 | HEPATITIS C VIRUS ENTRY INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20040147752-A1 | Carbazole derivatives for the treatment of NPY related diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-07-29 | — | — | US | disclosed |
| EP-1395578-A1 | CARBAZOLE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NPY RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002096902-A1 | CARBAZOLE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NPY RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147752-A1 | Carbazole derivatives for the treatment of NPY related diseases | NPY4R, NPY5R, NPY1R | MAPT 1696/4885MEN1 2674/4885KMT2A 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.